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Chimeric antigen receptor (CAR) T cell immunotherapy
uses patient-derived tumor antigen-directed T cells for
targeted elimination of cancer cells [1]. The most com-
mon form applies modified T cells expressing a CAR
specific for the CD19 antigen to treat relapsed or refrac-
tory lymphoma [2] and leukemia [3].
We present a 60-year-old female patient with refractory
diffuse large B cell lymphoma (DLBCL) who underwent
CAR T cell therapy. During treatment, all lesions de-
creased in size with a complete metabolic response
(Deauville score 1) in 18F-FDG PET/CT imaging obtained
3 months after CAR T cell infusion (A). At the same time,
multiple newly enlarged and hypermetabolic cervical
lymph nodes (SUVmax value = 31) were detected in a
previously unaffected location (B). These new lesions
(red circles and arrows) showed a morphological dediffer-
entiation with a large central hypodensity compared with
nodal DLBCL target lesions at baseline CT (blue circles
and arrows). This was also reflected by differences in the
radiomic features entropy and uniformity (C). These cir-
cumstances triggered a repeat histological workup that
determined the transformation of the DLBCL (D; high
CD20 expression) into a sarcoma of the dendritic cells
(E; high S100 expression) without residual lymphomatous
tissue. Based on high PD-L1 expression, checkpoint inhi-
bition with pembrolizumab was initiated.
Rare cases of transformation into histiocytic and dendritic
cell neoplasms have been reported in patients with follicular
lymphoma and DLBCL [4, 5]. This case underlines the di-
agnostic potential in the interlesional comparison of morpho-
logic and metabolic features to raise the suspicion of clonal
dedifferentiation. Future studies that correlate radiomic fea-
tures from imaging and pathologic features from biopsies
may not only lead to diagnostic improvements but also a
better understanding of tumor biology in patients undergoing
CAR T cell therapy.
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